ArticleMedComm2023
The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Article in MedComm, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 spike protein.Molecular biology and evolution · 2026Article
- Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants.The Journal of general virology · 2026Article
- Genome characterization of the SARS-CoV-2 omicron in Cameroon.BMC infectious diseases · 2026Article
- Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form.Small science · 2026Article
- A compartmental model of variant coexistence, dynamics and dominance in infectious diseases: Case for SARS-CoV-2 in Abu Dhabi.Infectious Disease Modelling · 2026Article
- Article
- Nationwide seroprevalence of SARS-CoV-2 Delta variant and five Omicron sublineages in companion cats and dogs in the USA: insights into their role in COVID-19 epidemiology.Emerging microbes & infections · 2025Article
- The virology of Omicron: pathophysiology, immune regulation, and clinical impact of SARS-CoV-2 sub variants.Virology journal · 2025Review
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 Spike protein.bioRxiv : the preprint server for biology · 2025Article
- Article
- Rapid, On-Site SARS-CoV‑2 Variant Detection and Differentiation Using GLAD-Pristine Silver Nanorod Arrays and Machine Learning-Enhanced SERS.ACS omega · 2025Article
- Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.Scientific reports · 2025Article
- Monitoring SARS-CoV-2 Dissemination in Wastewater and Virus Isolation in Cell Cultures: An Integrated Approach for Pathogen Detection and Surveillance.Journal of cellular and molecular medicine · 2025Article
- Analysis of the prevalence, spread, and mutation patterns of SARS-CoV-2 variants: data from COVID-19 testing expansion strategy study in salvador, Northeast Brazil.Scientific reports · 2025Article
- A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants.NPJ vaccines · 2025Article
- In silico genomic surveillance by CoVerage predicts and characterizes SARS-CoV-2 variants of interest.Nature communications · 2025Article
- Impact of imported COVID-19 cases on South Korea's response: variant transitions and regional patterns (2020-2023).BMC infectious diseases · 2025Article
- The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation.Journal of biomedical science · 2025Article
- SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis.Annals of clinical microbiology and antimicrobials · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the fifth variant of concern of the SARS-CoV-2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID-19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID-19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.